Beijing Zhongguancun Science-Technology Development Holding announced that its subsidiary Duoduo Pharmaceutical's tramadol hydrochloride injection, specification 2ml:100mg, was selected in the 12th batch of national organized drug centralized procurement, becoming one of five selected companies. The procurement cycle runs from the implementation date of the selection results until December 31, 2029, and medical institutions will prioritize selected products and ensure completion of agreed procurement volumes. The product is used to treat moderate to severe pain and is a Class B product under national medical insurance. Its sales revenue in 2025 was approximately 30.44 million yuan, accounting for 1.62% of the company's biomedical business revenue in 2025. The company stated that this selection will help increase product sales volume and market share, and enhance brand influence, while also noting that the signing of procurement contracts and subsequent market sales execution remain uncertain.
Beijing Centergate Technologies Holding Co LtdSelected in national procurement, expected to increase sales volume and market share.
